Header Logo

Connection

Doris Benbrook to CA-125 Antigen

Back to Details
This is a "connection" page, showing publications Doris Benbrook has written about CA-125 Antigen.
Doris Benbrook
Connection Strength
0.091
CA-125 Antigen
  1. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
    View in: PubMed
    Score: 0.091
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.